Merck & Company Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Free-Cash-Flow-To-The-Firm" stands at 13.68 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 06/30/2024.
Merck & Company Inc's third quarter result of 6.96 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 158.63 percent compared to it's second quarter result.
Also, Merck & Company Inc's third quarter result of 6.96 Billion USD for the item "Free Cash Flow To The Firm" represents a decrease of -19.72 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Merck & Company Inc's third quarter result of 13.68 Billion USD for the item "Free Cash Flow To The Firm" represents a decrease of -11.11 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -11.52 percent compared to the value the year prior.
The 1 year change in percent is -11.52.
The 3 year change in percent is -14.32.
The 5 year change in percent is 87.38.
The 10 year change in percent is 160.73.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Free Cash Flow To The Firm | 905,699,262,464.00 |
![]() | Johnson & Johnson - Free Cash Flow To The Firm | 486,508,953,600.00 |
![]() | AbbVie Inc - Free Cash Flow To The Firm | 399,570,305,024.00 |
![]() | Roche Holding AG - Free Cash Flow To The Firm | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Free Cash Flow To The Firm | 280,205,508,085.11 |